Gene News and Research

Latest Gene News and Research

New research: NFKBIA gene loss induces glioblastoma development

New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Urine tests could detect Obsessive Compulsive Disorder

Australian researchers have found a novel and easy way to detect a common and debilitating anxiety disorder called the Obsessive Compulsive Disorder or OCD. Scientists at the Centenary Institute in Sydney discovered a gene responsible for a rare kidney disorder is also behind OCD. This may make detecting OCD easier through a simple urine test. This test could also identify babies with risk of early-onset OCD. OCD affects up to 3 per cent of all Australians and in its worst cases can be completely debilitating, causing people to have to stay at home. OCD sufferers feel intense anxiety and are compelled to practice rituals - such as hand washing or arranging objects.

6 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

JMD publishes results of Tissue of Origin Test validation, reproducibility study

Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced today that The Journal of Molecular Diagnostics has published the results of a significant Tissue of Origin Test validation and reproducibility study.

6 Jan 2011

Novel AAV gene therapy offers various advantages

A new, simplified method for producing large amounts of viral vector cassettes capable of shuttling genes into host cells will help advance the promising field of gene therapy as applications move into large animal studies and human clinical trials.

6 Jan 2011

Signal Genetics, Caris Life Sciences announce new agreement to commercialize MyPRS tool

Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.

6 Jan 2011

Mutated TDP-43 can cause neurons to die: Study

Lou Gehrig's disease, or amyotrophic lateral sclerosis, and frontotemporal lobar degeneration are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Study provides new insights into how viruses establish chronic infections

Walter and Eliza Hall Institute researchers in Melbourne, Australia, have discovered how a key viral gene helps viruses evade early detection by the immune system. Their finding is providing new insights into how viruses are able to establish chronic infections, leading scientists to reevaluate their approaches to viral vaccine development.

6 Jan 2011

Mayo Clinic researchers estimate lifetime risk of developing rheumatoid arthritis in men and women

Mayo Clinic researchers have determined the lifetime risk of developing rheumatoid arthritis and six other autoimmune rheumatic diseases for both men and women. The findings appear online in Arthritis and Rheumatism.

6 Jan 2011

Scientists discover that skin cancer can spread to lungs through cell blocking activity

CANCER RESEARCH UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked. The research is published in Cancer Cell.

6 Jan 2011

Researchers say women with multiple sclerosis have more HLA genes than men

Women who have multiple sclerosis (MS) are more likely to have a gene associated with multiple sclerosis than men with the disease and it is this gene region where environment interacts with the genetics, according to a study published in the January 5, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

6 Jan 2011

Odyssey Thera granted U.S. Patent for high-throughput screening of proteins

Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that the company will enter a collaborative R&D agreement with the National Institute of Biomedical Innovation (NIBIO; Director General: Koichi Yamanishi; Osaka, Japan), which could offer new hepatocyte derived from human iPS (induced pluripotent stem) cells used for an effective in-vitro drug screening for hepatic toxicity and liver metabolism.

5 Jan 2011

Safe vaccine protects mice against effects of cocaine

Researchers have produced a lasting anti-cocaine immunity in mice by giving them a safe vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

5 Jan 2011

Critical tuning dial for controlling whole body energy

Researchers have found what appears to be a critical tuning dial for controlling whole body energy, according to a new report in the January issue of Cell Metabolism, a Cell Press publication. When energy levels within cells drop, it sets off a series of events designed to increase the amount of calorie-rich dietary fat that the body will absorb.

5 Jan 2011

Gene News and Research

Latest Gene News and Research

New research: NFKBIA gene loss induces glioblastoma development

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Urine tests could detect Obsessive Compulsive Disorder

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

JMD publishes results of Tissue of Origin Test validation, reproducibility study

Novel AAV gene therapy offers various advantages

Signal Genetics, Caris Life Sciences announce new agreement to commercialize MyPRS tool

Mutated TDP-43 can cause neurons to die: Study

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Study provides new insights into how viruses establish chronic infections

Mayo Clinic researchers estimate lifetime risk of developing rheumatoid arthritis in men and women

Scientists discover that skin cancer can spread to lungs through cell blocking activity

Researchers say women with multiple sclerosis have more HLA genes than men

Odyssey Thera granted U.S. Patent for high-throughput screening of proteins

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

ReproCELL to enter collaborative iPS cell-derived hepatocytes R&D agreement with NIBIO

Safe vaccine protects mice against effects of cocaine

Critical tuning dial for controlling whole body energy

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy